FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035566238> ?p ?o ?g. }

• W2035566238 endingPage "1668" @default.
• W2035566238 startingPage "1661" @default.
• W2035566238 abstract "A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) describe the toxicities of this regimen; and (iii) evaluate the plasma pharmacokinetic parameters and extent of PARP inhibition in peripheral blood mononuclear cells (PBMCs) following veliparib.TMZ was given once daily and veliparib twice daily for 5 days every 28 days. Veliparib concentrations and poly(ADP-ribose) (PAR) levels in PBMCs were measured on days 1 and 4. Analysis of pharmacokinetic and PBMC PAR levels were performed twice during study conduct to rationally guide dose modifications and to determine biologically optimal MTD/RP2D.Twenty-nine evaluable patients were enrolled. Myelosuppression (grade 4 neutropenia and thrombocytopenia) were dose limiting. The RP2Ds are veliparib 25 mg/m(2) b.i.d. and TMZ 135 mg/m(2)/d. Only 2 out of 12 patients treated at RP2Ds experienced dose-limiting toxicities. Although no objective response was observed, 4 patients had stable disease >6 months in duration, including 1 with glioblastoma multiforme and 1 with ependymoma. At the RP2D of veliparib, pediatric pharmacokinetic parameters were similar to those in adults.Veliparib and TMZ at the RP2D were well tolerated in children with recurrent brain tumors. A phase I/II trial to evaluate the tolerability and efficacy of veliparib, TMZ, and radiation in children with newly diagnosed brainstem gliomas is in progress." @default.
• W2035566238 created "2016-06-24" @default.
• W2035566238 creator A5004353294 @default.
• W2035566238 creator A5016039890 @default.
• W2035566238 creator A5016812694 @default.
• W2035566238 creator A5020161845 @default.
• W2035566238 creator A5027468886 @default.
• W2035566238 creator A5029492518 @default.
• W2035566238 creator A5042463331 @default.
• W2035566238 creator A5044312349 @default.
• W2035566238 creator A5045409088 @default.
• W2035566238 creator A5055567714 @default.
• W2035566238 creator A5065578155 @default.
• W2035566238 creator A5066196706 @default.
• W2035566238 creator A5067969166 @default.
• W2035566238 creator A5068058971 @default.
• W2035566238 creator A5071378074 @default.
• W2035566238 creator A5076645797 @default.
• W2035566238 creator A5080784534 @default.
• W2035566238 creator A5087951266 @default.
• W2035566238 date "2014-06-07" @default.
• W2035566238 modified "2023-10-14" @default.
• W2035566238 title "A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†" @default.
• W2035566238 cites W1983642662 @default.
• W2035566238 cites W2006268714 @default.
• W2035566238 cites W2034428009 @default.
• W2035566238 cites W2041539034 @default.
• W2035566238 cites W2047082284 @default.
• W2035566238 cites W2049921243 @default.
• W2035566238 cites W2051701101 @default.
• W2035566238 cites W2054172055 @default.
• W2035566238 cites W2056920544 @default.
• W2035566238 cites W2061001563 @default.
• W2035566238 cites W2074064462 @default.
• W2035566238 cites W2075174658 @default.
• W2035566238 cites W2076106771 @default.
• W2035566238 cites W2076809452 @default.
• W2035566238 cites W2086038769 @default.
• W2035566238 cites W2099293048 @default.
• W2035566238 cites W2102872615 @default.
• W2035566238 cites W2106729876 @default.
• W2035566238 cites W2106893529 @default.
• W2035566238 cites W2110017381 @default.
• W2035566238 cites W2114572046 @default.
• W2035566238 cites W2115992142 @default.
• W2035566238 cites W2118682535 @default.
• W2035566238 cites W2131670056 @default.
• W2035566238 cites W2139596299 @default.
• W2035566238 cites W2140010849 @default.
• W2035566238 cites W2146176862 @default.
• W2035566238 cites W2155851270 @default.
• W2035566238 cites W2156077962 @default.
• W2035566238 cites W2156442575 @default.
• W2035566238 cites W2156976216 @default.
• W2035566238 cites W2163865152 @default.
• W2035566238 cites W2164459955 @default.
• W2035566238 cites W2171208628 @default.
• W2035566238 cites W2247465456 @default.
• W2035566238 cites W3093265161 @default.
• W2035566238 doi "https://doi.org/10.1093/neuonc/nou103" @default.
• W2035566238 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4232081" @default.
• W2035566238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24908656" @default.
• W2035566238 hasPublicationYear "2014" @default.
• W2035566238 type Work @default.
• W2035566238 sameAs 2035566238 @default.
• W2035566238 citedByCount "57" @default.
• W2035566238 countsByYear W20355662382014 @default.
• W2035566238 countsByYear W20355662382015 @default.
• W2035566238 countsByYear W20355662382016 @default.
• W2035566238 countsByYear W20355662382017 @default.
• W2035566238 countsByYear W20355662382018 @default.
• W2035566238 countsByYear W20355662382019 @default.
• W2035566238 countsByYear W20355662382020 @default.
• W2035566238 countsByYear W20355662382021 @default.
• W2035566238 countsByYear W20355662382022 @default.
• W2035566238 countsByYear W20355662382023 @default.
• W2035566238 crossrefType "journal-article" @default.
• W2035566238 hasAuthorship W2035566238A5004353294 @default.
• W2035566238 hasAuthorship W2035566238A5016039890 @default.
• W2035566238 hasAuthorship W2035566238A5016812694 @default.
• W2035566238 hasAuthorship W2035566238A5020161845 @default.
• W2035566238 hasAuthorship W2035566238A5027468886 @default.
• W2035566238 hasAuthorship W2035566238A5029492518 @default.
• W2035566238 hasAuthorship W2035566238A5042463331 @default.
• W2035566238 hasAuthorship W2035566238A5044312349 @default.
• W2035566238 hasAuthorship W2035566238A5045409088 @default.
• W2035566238 hasAuthorship W2035566238A5055567714 @default.
• W2035566238 hasAuthorship W2035566238A5065578155 @default.
• W2035566238 hasAuthorship W2035566238A5066196706 @default.
• W2035566238 hasAuthorship W2035566238A5067969166 @default.
• W2035566238 hasAuthorship W2035566238A5068058971 @default.
• W2035566238 hasAuthorship W2035566238A5071378074 @default.
• W2035566238 hasAuthorship W2035566238A5076645797 @default.
• W2035566238 hasAuthorship W2035566238A5080784534 @default.
• W2035566238 hasAuthorship W2035566238A5087951266 @default.
• W2035566238 hasBestOaLocation W20355662381 @default.
• W2035566238 hasConcept C104317684 @default.
• W2035566238 hasConcept C112705442 @default.

• next